Aktie A12CT3 MARKSANS PHARMA LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Marksans Pharma Limited Bombay S.E.

Aktien

A12CT3

INE750C01026

MARKSANS

Markt geschlossen - Bombay S.E.
Andere Börsenplätze
 12:00:49 03.05.2024 		% 5 Tage % 1. Jan.
166.2 INR -0.81% Intraday Chart für Marksans Pharma Limited -3.48% +3.33%
14.02. Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024
13.02. Marksans Pharma Limited meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets
Marksans Pharma Undergoes Successful Inspection from German Health Authorities
CARE Affirms A+ Rating on Marksans Pharma's Long-term Bank Financing; Outlook Stable
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg
Marksans Pharma Limited Approves Payment of Dividend
Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director
Marksans Pharma Gets US FDA's Final Approval for Generic Cough Medicine
Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23
Marksans Pharma's Goa Plant Gets Two Observations from US FDA
Marksans Pharma Gets US FDA Nod for Pain Relief Drug
Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg
Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023
Marksans Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A12CT3 Aktie
  4. A12CT3 Aktie
  5. Nachrichten Marksans Pharma Limited
  6. Andere Sprachen